Summary:
The purpose of this Phase III study is to evaluate the efficacy and safety of MEDI3506
300 mg every 8 weeks (Q8W) and 300 mg every 4 weeks (Q4W) dose regimens administered
subcutaneously (SC) in adult participants with symptomatic COPD and history of
≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months.
Criteria:- 40 or older with documented diagnosis of COPD for at least one year
- ICS/LABA/LAMA triple therapy, or dual therapy if triple is not indicated or contraindicated) and at a stable dose for at least 3 months
- Smoking history of ≥ 10 pack-years (1 pack a day for 10 years or less packs for more than 10 years).
- Able to read and use electronic devices.
Qualified Participants May Receive:
300 mg of either placebo or IP every 4 weeks. Treatment will be blinded to both subejct and study doctor. After treatment completion, there may be an additional extension for the study and for the patient to continue on treatment.